MEDANTA Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Medanta delivered a strong Q2 FY27 with 34% YoY revenue growth to INR 14,690 million, 60% YoY operating EBITDA growth to INR 3,701 million (25.2% margin vs 21% YoY), and 38% YoY PAT growth to INR 2,191 million. Noida achieved EBITDA breakeven within a year, validating the model's scalability. Volume growth was robust across clusters, driven by capacity additions and clinical talent hiring. The company has a robust expansion pipeline of ~3,450 beds over next few years with planned capex of over INR 6,000 crores. Key risks include regulatory uncertainty around oncology drug margin capping, seasonality in Q3, and construction delays at Pitampura. Overall outlook remains positive with management focused on long-term sustainable growth.
Management Tone
- Prepared Remarks: Great — Prepared remarks highlighted strong operational and financial metrics: 34% revenue growth, 60% EBITDA growth, Noida EBITDA breakeven, 30% increase in inpatient volumes, and a clear expansion pipeline. The tone was confident and forward-looking, with a clear articulation of strategy and capacity expa
- Q&A Session: Good — Analysts asked substantive questions on margins, capacity expansion, and regulatory changes. Management provided direct, detailed answers, including specific volume growth figures (e.g., 26% ex-Noida in Cluster 2) and clarifications on corporate cost allocation. However, there was some caution aroun
Revenue Growth Drivers
- Volume growth across network (inpatient +30% YoY, outpatient +38% YoY)
- Cluster 2 ramp-up (Noida, Lucknow, Patna)
- Capacity additions (bed additions, new operating theatres, cath labs)
Growth vs Margin Focus
Management is focused on driving growth through volume, capacity expansion, and clinical talent additions, while simultaneously benefiting from operating leverage as hospitals scale up. The Noida EBITDA breakeven demonstrates the model's ability to achieve margins as scale increases. Management expl
About Global Health Limited (Medanta)
Global Health Limited (Medanta) (MEDANTA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.